188 results on '"Barta, Stefan"'
Search Results
2. Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B Cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy
3. Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease
4. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
5. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
6. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome
7. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
8. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
9. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
10. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies
11. Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial
12. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
13. TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era
14. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
15. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study
16. SOHO State of the Art Updates and Next Questions | Challenging Cases in Rare T-Cell Lymphomas
17. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells
18. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
19. Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
20. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
21. Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
22. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
23. Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting
24. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
25. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
26. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States
27. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
28. Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes
29. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
30. Brentuximab vedotin in the treatment of CD30+ PTCL
31. A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening
32. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
33. EXABS-111-NHL Challenging Cases in Rare T-Cell Lymphomas
34. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma
35. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
36. Splenic irradiation for splenomegaly: A systematic review
37. Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis
38. Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome
39. Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?
40. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study
41. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
42. Postibrutinib relapse outcomes for patients with marginal zone lymphoma
43. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients
44. TCL-320 Single Institution Experience of Pembrolizumab for Patients with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome
45. TCL-664 Clinical Characteristics of Patients With Peripheral T-Cell Lymphoma (PTCL) and Concomitant Hepatitis B Virus (HBV) Infection
46. TCL-394 Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
47. Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
48. Clinical Characteristics of Patients With Peripheral T-Cell Lymphoma (PTCL) and Concomitant Hepatitis B Virus (HBV) Infection
49. Single Institution Experience of Pembrolizumab for Patients with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome
50. Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.